EGFR and neoplasm: Recent studies further demonstrate that KRAS-G12C inhibition leads to heterogeneous cellular responses, with subsets of tumor cells escaping via rapid re-synthesis of active, drug-insensitive KRAS protein, maintained through EGFR and Aurora kinase (AURK) signaling17,19.